This often precedes ad inventory value increases in programmatic auctions. Overview: Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases, with a market cap of $87.12 million. The net loss improved to $1.7 million compared to $3.4 million in the previous year, reflecting a ~50% year-over-year improvement. Analysts tie the inuv stock forecast 2025 to global ad-tech sector expansions. Expected investments in privacy-compliant data solutions could enhance INUV’s competitiveness and margin stability in Q2–Q3
